GIUSEPPE DI BELLA
Stable and objective remission of 12 prostate cancer patients treated only with The Bella Method (MDB)
OBJECTIVE: To evaluate the objective clinical, biochimical and metabolical … response and the safety of the combined administration of Di Bella Method (DBM) in patients with a histological diagnosis of prostate adenocarcinoma.
MATERIALS AND METHODS: Twelve patients with a certain diagnosis of prostate cancer and with measurable disease characteristics were evaluated according to the RECIST criteria. The 12 patients had not been previously operated on or chemo-radiotreated. After giving informed consent, they voluntarily accepted the administration of the treatment as first-line therapy.
In detail, they were administered in the following ways:
• All-trans retinoic acid solution (ATRA, 1543488.372 IU), axerophthol palmitate (909000 IU), beta-carotene (3334000 IU) in alpha tocopheryl acetate (1000000 IU), in a stoichiometric ratio of 1: 1: 4: 2; 2-3 in conjunction with
• Dihydrotachisterol (cholecalciferol-Vit.D3, ATITEN ©; 15200 IU);
• Somatostatin: scalar administration;
• Tetracosactide (Synachten® – synthesis ACTH) with frequent monitoring of blood pressure and blood sugar;
• Octreotide LAR (slow release) 30 mg intramuscular;
• Enantone 3.75mg intramuscolar;
• Bicatulamide (Casodex®) 50 mg;
• Melatonin 5 mg;
• Cabergoline 0.25 mg;
• Bromocriptina® 2.5 mg;
• Cyclophosphamide® (from 50 mg to 75mg) gradual dosage;
• Ascorbic acid (Vit C) gradual dosage, with
• Carbonate calcium 500 mg in the same glass;
• Chondroitin sulfate 250 mg + Glucosamine 250 mg;
• Calciolevofolinate 22 mg
RESULTS AND CONCLUSIONS: This preliminary study shows that all 12 patients not previously treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit and they alla achieved a five-year stable objective clinical instrumental, metabolic, biochemical complete remission with DBM applied as first-line therapy. Further clinical inestigations are recommended.